Lipid management with statins: The lower the better?

Zeitschrift fur Kardiologie

Volumn 93, Issue 1, 2004, Pages 4-9

  Laufs, U ^a   Liao, J K ^b   Bohm M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cholesterol; Lipid lowering; Review; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG COST; DRUG EFFECT; DRUG SAFETY; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; REVIEW; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES; REFERENCE VALUES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0842264990     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-004-1023-y     Document Type: Review

References (32)

1. National Cholesterol Education Program Expert Panel (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart, Lung, and Blood Institute, National Institutes of Health, Publication No 02-5215, pp 3143-3421
2. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T (1997) Single LDL-C apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95:76-82
3. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr (1990) Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323: 946-955
4. Werner N, Nickenig G, Laufs U (2002) Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol. 97:105-116
5. Dietz R, Rauch B (2003) Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie - Herz-und Kreislaufforschung (DGK). Deutsche Gesellschaft für Kardiologie - Herz-und Kreislaufforschung
6. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB, Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 41:159-168
7. Pitt B, Waters D, Brown WV, van BA, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341:70-76
8. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIR-ACL study: a randomized controlled trial. JAMA 285:1711-1718
9. Heart Protection Study Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
11. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
12. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Böhm M, Nickenig G (2001) Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59:646-654
13. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK (2001) Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108:1429-1437
14. Laufs U, Liao JK (2000) Targeting Rho in Cardiovascular Disease. Circ Res 87:526-528
15. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690
16. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965
17. Sukhova GK, Williams JK, Libby P (2002) Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22:1452-1458
18. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, Schmieder RE (2001) Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 37:1351-1358
19. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A (2001) Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104:376-379
20. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW (1999) Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33:234-241
21. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, Takeshita A (2001) Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 88:1291-1294
22. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, Nickenig G (2001) Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88: 1306-1307
23. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD (2002) Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 105:1446-1452
24. Thomas M, Mann J (1998) Increased thrombotic vascular events after change of statin. Lancet. 352:1830-1831
25. Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310-315
26. Stamler J, Wentworth D, Neaton J, for the MRFIT Research Group (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256:2823-2828
27. Kannel W (1995) Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:69C-77C
28. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009
29. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD (2002) Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 102:1893-1900
30. Shepherd J (2002) Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 359: 2271-2273
31. Arzneimittelkommission der Deutschen Ärzteschaft (www.akdae.de) (2002) Therapieempfehlung Fettstoffwechselstörungen. Dt Ärzte-Verl Köln, S 169-189
32. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C (2002) ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 106: 1024-1028